CN116327814A - 一种降血脂、降胆固醇的组合物及其制备方法和用途 - Google Patents
一种降血脂、降胆固醇的组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN116327814A CN116327814A CN202211096185.1A CN202211096185A CN116327814A CN 116327814 A CN116327814 A CN 116327814A CN 202211096185 A CN202211096185 A CN 202211096185A CN 116327814 A CN116327814 A CN 116327814A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- cholesterol
- preparation
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 230000001603 reducing effect Effects 0.000 title claims abstract description 26
- 239000008280 blood Substances 0.000 title claims abstract description 24
- 210000004369 blood Anatomy 0.000 title claims abstract description 24
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 27
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 27
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 27
- 229960004999 lycopene Drugs 0.000 claims abstract description 27
- 235000012661 lycopene Nutrition 0.000 claims abstract description 27
- 239000001751 lycopene Substances 0.000 claims abstract description 27
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 24
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims abstract description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 9
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 238000009098 adjuvant therapy Methods 0.000 claims description 4
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 1
- 229940026314 red yeast rice Drugs 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000252212 Danio rerio Species 0.000 description 23
- 239000000047 product Substances 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 9
- 235000007189 Oryza longistaminata Nutrition 0.000 description 9
- 240000007594 Oryza sativa Species 0.000 description 9
- 235000007164 Oryza sativa Nutrition 0.000 description 9
- 229960001770 atorvastatin calcium Drugs 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 6
- 229940075999 phytosterol ester Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 208000032928 Dyslipidaemia Diseases 0.000 description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 description 5
- 210000002969 egg yolk Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009372 pisciculture Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 108700024526 zebrafish sox32 Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及医药技术领域,具体涉及一种降血脂、降胆固醇的组合物及其制备方法和用途,包括如下重量份的组分:植物甾醇或其类似物200‑1000重量份、红曲提取物50‑500重量份和番茄红素10‑500重量份;上述组合物中,通过将植物甾醇或其类似物、红曲提取物和番茄红素复配,发现植物甾醇或其类似物、红曲提取物和番茄红素具有协同降低血脂、降胆固醇的作用,可以用于制备降血脂、降胆固醇的产品,具有制备预防、缓解、辅助治疗或治疗高血脂和/或高胆固醇的产品中的用途。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种降血脂、降胆固醇的组合物及其制备方法和用途。
背景技术
近年,人群的血脂水平逐步升高,血脂异常患病率明显增加,成人血脂异常总体患病率高达40.40%,同时儿童青少年高胆固醇血症患病率也有明显升高,血脂异常总患病率为23.5%。这预示未来成人血脂异常患病及相关疾病负担将继续加重。血脂异常是心血管疾病重要的危险因素。目前,心血管疾病逐渐成为世界人口尤其是发展中国家致死人数最多的疾病类群。高血脂作为“三高”之一,即血清胆固醇及甘油三酯的升高,与高血压、动脉粥样硬化等心血管疾病存在显著相关性。因此,降血脂和降胆固醇成为“三高”患者亟待解决的问题。
发明内容
因此,本发明要解决的技术问题在于提供一种降血脂、降胆固醇的组合物及其制备方法和用途。
为此,本发明提供了如下的技术方案:
一种降血脂、降胆固醇的组合物,包括如下重量份的组分:植物甾醇或其类似物200-1000重量份、红曲提取物50-500重量份和番茄红素10-500重量份。
可选的,包括如下重量份的组分:植物甾醇或其类似物400-800重量份、红曲提取物150-300重量份和番茄红素50-200重量份。
可选的,包括如下重量份的组分:植物甾醇或其类似物754重量份、红曲提取物114.9重量份和番茄红素99.5重量份;或
植物甾醇或其类似物682重量份、红曲提取物280重量份和番茄红素99重量份。
一种所述的降血脂、降胆固醇的组合物的制备方法,包括:按照配方称取原料,混合。
一种制剂,以所述的降血脂、降胆固醇的组合物为活性成分。
可选的,还包括制剂允许的赋形剂或载体;
可选的,所述制剂的形式包括液体制剂和固体制剂;
可选的,所述制剂的形式包括注射剂、片剂、胶囊剂、粉剂、颗粒剂或膏剂。
所述的降血脂、降胆固醇的组合物或所述的制剂具有如下的用途:
(1)制备降血脂和/或降胆固醇的产品中的用途;
(2)制备预防、缓解、辅助治疗或治疗高血脂和/或高胆固醇的产品中的用途;
(3)制备降低甘油三脂的产品中的用途;
(4)制备降低hmgcra基因表达水平的产品中的用途;
(5)制备减肥的产品中的用途。
可选的,所述产品包括食品、食品添加剂或药品。
可选的,所述食品包括功能性食品、保健品或普通食品。
本发明技术方案,具有如下优点:
1.本发明提供的一种降血脂、降胆固醇的组合物,包括如下重量份的组分:植物甾醇或其类似物200-1000重量份、红曲提取物50-500重量份和番茄红素10-500重量份;上述组合物中,通过将植物甾醇或其类似物、红曲提取物和番茄红素复配,发现植物甾醇或其类似物、红曲提取物和番茄红素具有协同降低血脂、降胆固醇的作用,可以用于制备降血脂、降胆固醇的产品,具有制备预防、缓解、辅助治疗或治疗高血脂和/或高胆固醇的产品中的用途。
具体实施方式
提供下述实施例是为了更好地进一步理解本发明,并不局限于所述最佳实施方式,不对本发明的内容和保护范围构成限制,任何人在本发明的启示下或是将本发明与其他现有技术的特征进行组合而得出的任何与本发明相同或相近似的产品,均落在本发明的保护范围之内。
实施例中未注明具体实验步骤或条件者,按照本领域内的文献所描述的常规实验步骤的操作或条件即可进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规试剂产品。
植物甾醇或其类似物为市售产品,其产品形式包括但不限于植物甾醇或其类似物的微囊粉、膏剂或油剂,总甾醇含量为50%以上,可以购自任何厂家,下述实施例中的植物甾醇或其类似物选择使用植物甾醇酯,植物甾醇酯购自巴斯夫(BASF Corporation)公司。
番茄红素为市售产品,其产品形式包括但不限于番茄红素微囊粉、番茄红素膏、番茄红素油或番茄红素结晶性粉末,番茄红素含量为5%以上,可以购自任何厂家,下述实施例中的番茄红素油购自晨光生物科技集团股份有限公司。
红曲提取物为市售产品,其产品形式包括但不限于红曲粉、红曲米或红曲提取液,洛伐他汀含量为≥1%,可以购自任何厂家,下述实施例和实验例中的红曲提取物购自杭州双马生物科技股份有限公司的红曲粉。
实施例
实施例1-7的降血脂、降胆固醇的组合物的配方如下表。
表1、降血脂、降胆固醇的组合物的配方
实施例1-7的降血脂、降胆固醇的组合物的制备方法,包括:按照上述表1的配方,称取原料,混合均匀,即得。
实验例
1.检测材料
1.1.样品配制信息
样品:实施例1-7的降血脂、降胆固醇的组合物、单独的植物甾醇酯、单独的红曲提取物或单独的番茄红素油用DMSO(分析纯)配制成100mg/mL母液,-20℃储存。
阳性对照:阿托伐他汀钙片(以下简称阿托伐他汀钙),白色片剂,批号202105219C,乐普医疗,阴凉避光储存。用DMSO配制成11.6mg/mL母液,-20℃分装储存。
1.2.实验动物
斑马鱼均饲养于28℃的养鱼用水中(水质:每1L反渗透水中加入200mg速溶海盐,电导率为450~550μS/cm;pH为6.5~8.5;硬度为50~100mg/L CaCO3),实验动物使用许可证号为:SYXK(浙)2022-0004。饲养管理符合国际AAALAC认证(认证编号:001458)的要求。
斑马鱼为黑色素等位基因突变型半透明Albino品系斑马鱼,以自然成对交配繁殖方式进行。年龄为受精后5天(5dpf)的斑马鱼用于降血脂、降低胆固醇功效最大检测浓度(MTC)测定及其功效评价。
1.3.仪器、耗材与试剂
解剖显微镜(SZX7,OLYMPUS,日本);显微注射仪(IM300,Narishige,日本);拉针仪(PC-10,Narishige,日本);CCD相机(VertA1,上海土森视觉科技有限公司,中国);电动聚焦连续变倍荧光显微镜(AZ100,Nikon,日本);精密电子天平(CP214,OHAUS,美国);6孔板(Nest Biotech,中国);普通PCR扩增仪(T100,BIO-RAD,新加坡);荧光定量PCR仪(CFXConnect,BIO-RAD,新加坡);高速冷冻离心机(Heraeus Fresco17,ThermoFisher,德国);紫外-可见光分光光度计(Nanodrop2000,Thermo,奥地利);微孔板迷你离心机(BE-6100,海门市其林贝尔仪器制造有限公司,中国);PCR96孔板(货号MQ50801S×5,莫纳生物科技有限公司,中国);光学粘性封膜B(MSB1001,Bio-rad,美国)。
二甲基亚砜(DMSO,批号BCCD8942,Sigma,瑞士);甲基纤维素(批号B2006074,上海阿拉丁生化科技股份有限公司,中国);cholesterlylBODIPYTM542/563C11(胆固醇荧光探针,批号2291600,invitrogen,美国);油红O(Oil Red O,批号SHBM5455,Sigma,美国);1.2-丙二醇(批号20210817,国药集团化学试剂有限公司,中国);纯蛋黄粉(批号20200809,浙江艾格生物科技股份有限公司,中国);D-(+)-葡萄糖(批号20201105,国药集团化学试剂有限公司,中国);无水乙醇(批号20210107,国药集团化学试剂有限公司,中国);FastQuant RTKit(With gDNase)试剂盒(货号KR106,TIANGEN,中国);RNA-Quick Purification Kit(RNA快速提取试剂盒)(货号RN001,YiShan Biotech,中国);PowerUpTMSYBRTMGreenMasterMix(货号A25742,赛默飞世尔科技(中国)有限公司,中国)。
2.检测方法
2.1.MTC测定
随机选取5dpf黑色素等位基因突变型半透明Albino品系斑马鱼于烧杯中,每烧杯(实验组)30尾。分别水溶给予阿托伐他汀钙、样品(终浓度见表2),同时设置正常对照组和模型对照组,每杯容量为25mL。除正常对照组外,其余各实验组均水溶给予高脂饲料(高脂饲料为葡萄糖终浓度3wt%,终浓度蛋黄粉1.5mg/mL),建立斑马鱼高血脂模型。样品与高脂饲料共同处理15h(每天共同处理7.5h,每天余下的时间饲养于28℃的养鱼用水中)。样品处理期间,每天统计各实验组的斑马鱼死亡数量并及时移除。28℃处理48h后,测定阿托伐他汀钙、样品对模型斑马鱼的最小中毒浓度(MTC)。
2.2.降甘油三酯功效评价
随机选取5dpf黑色素等位基因突变型半透明Albino品系斑马鱼于烧杯中,每烧杯30尾。分别水溶给予阿托伐他汀钙、样品(终浓度见表3),同时设置正常对照组和模型对照组,每杯容量为25mL。除正常对照组外,其余各实验组均水溶给予高脂饲料(高脂饲料为葡萄糖终浓度3wt%,蛋黄粉终浓度1.5mg/mL),建立斑马鱼高血脂模型。样品与高脂饲料共同处理15h(每天共同处理7.5h,每天余下的时间饲养于28℃的养鱼用水中)。28℃处理48h后,给予油红O进行整体脂肪染色。染色结束后,每个实验组随机选取10尾斑马鱼在解剖显微镜下拍照,用Image-J高级图像处理软件分析并采集数据,分析斑马鱼尾部血管染色强度,以该指标的统计学分析结果评价阿托伐他汀钙、样品降甘油三酯功效。统计学处理结果采用mean±SE表示。用SPSS26.0软件进行统计学分析,p<0.05表明差异具有统计学意义。
2.3.降胆固醇功效评价
随机选取5dpf黑色素等位基因突变型半透明Albino品系斑马鱼于烧杯中,每烧杯30尾。分别水溶给予阿托伐他汀钙、样品(终浓度见表4),同时设置正常对照组和模型对照组,每杯容量为25mL。除正常对照组外,其余各实验组均水溶给予高脂饲料(高脂饲料为葡萄糖终浓度3wt%,蛋黄粉终浓度1.5mg/mL),建立斑马鱼高血脂模型。样品与高脂饲料共同处理15h(每天共同处理7.5h,每天余下的时间饲养于28℃的养鱼用水中)。28℃处理32h后,给予胆固醇荧光探针(终浓度1mg/mL)。继续处理16h,每个实验组随机选取10尾斑马鱼在荧光显微镜下拍照,用NIS-Elements D3.20高级图像处理软件分析并采集数据,分析斑马鱼尾部血管胆固醇荧光强度,以该指标的统计学分析结果评价样品降胆固醇功效。统计学处理结果采用mean±SE表示。用SPSS26.0软件进行统计学分析,p<0.05表明差异具有统计学意义。
2.4.对hmgcra基因相对表达量的影响
随机选取5dpf黑色素等位基因突变型半透明Albino品系斑马鱼于烧杯中,每烧杯30尾。分别水溶给予阿托伐他汀钙、样品(终浓度见表7),同时设置正常对照组和模型对照组,每杯容量为25mL。除正常对照组外,其余各实验组均水溶给予高脂饲料(高脂饲料为葡萄糖3wt%,蛋黄粉1.5mg/mL),建立斑马鱼高血脂模型。样品与高脂饲料共同处理15h(每天共同处理7.5h)。28℃处理48h后,使用RNA快速提取试剂盒提取各组斑马鱼总RNA,利用紫外-可见光分光光度计对总RNA浓度和纯度进行测定。取2.00μg斑马鱼样品总RNA,按照cDNA第一链合成试剂盒说明操作,合成20.0μL cDNA,通过q-PCR检测β-actin和hmgcra基因的表达(引物序列见表6)。用β-actin作为基因表达的内参,计算hmgcra基因的RNA相对表达量。统计学处理结果采用mean±SE表示。用SPSS26.0软件进行统计学分析,p<0.05表明差异具有统计学意义。
3.检测结果
3.1.MTC
在本实验条件下,阿托伐他汀钙对模型斑马鱼的MTC为11.6μg/mL。详见下表。
表2.样品的MTC实验结果(n=30)
3.2.降甘油三脂功效评价
结果见下表。
表3、降甘油三脂功效评价
注:与模型对照组比较,*P<0.05,**P<0.01,***P<0.001;不同字母具有显著性差异(P<0.05)。
由上表可知,相比模型对照组,阳性对照组、本发明实施例1-7的降血脂、降胆固醇的组合物以及单独的植物甾醇酯、单独的红曲提取物或单独的番茄红素油均能够显著降低甘油三脂(P<0.05)。实施例1-7的降血脂、降胆固醇的组合物相比单独的植物甾醇酯、单独的红曲提取物或单独的番茄红素油,在降低甘油三脂方面具有显著的差异,说明本发明的降血脂、降胆固醇的组合物能够协同降低甘油三脂。
3.3.降胆固醇功效评价
结果见下表。
表4、降胆固醇功效评价
注:与模型对照组比较,*P<0.05,**P<0.01,***P<0.001;
由上表可知,相比模型对照组,阳性对照组、本发明实施例1-7的降血脂、降胆固醇的组合物能够显著降低胆固醇(P<0.05)。实施例1-7的降血脂、降胆固醇的组合物相比单独的植物甾醇酯、单独的红曲提取物或单独的番茄红素油,在降低胆固醇方面具有显著的差异,说明本发明的降血脂、降胆固醇的组合物能够协同降低胆固醇。
3.4.对hmgcra基因相对表达量的影响
在实验终点,提取斑马鱼总RNA,用紫外-可见光分光光度计测定RNA的浓度及A260/A280比值(表5),A260/A280比值均在1.8-2.2之间,表明提取得到斑马鱼总RNA质量较好,可用于后续q-PCR实验。引物序列见表6。
表5.总RNA的浓度及A260/A280比值(n=30)
表6.引物序列信息
结果见下表。
表7、hmgcra基因相对表达量
注:与模型对照组比较,*P<0.05,**P<0.01,***P<0.001。不同字母具有显著性差异(P<0.05)。
由上表可知,相比模型对照组,阳性对照组、本发明实施例1-7的降血脂、降胆固醇的组合物以及单独的植物甾醇酯、单独的红曲提取物或单独的番茄红素油能够显著降低hmgcra基因相对表达量(P<0.05)。实施例1-7的降血脂、降胆固醇的组合物相比单独的植物甾醇酯、单独的红曲提取物或单独的番茄红素油,在降低hmgcra基因相对表达量方面更显著,说明本发明的降血脂、降胆固醇的组合物能够协同降低hmgcra基因相对表达量。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (9)
1.一种降血脂、降胆固醇的组合物,其特征在于,包括如下重量份的组分:植物甾醇或其类似物200-1000重量份、红曲提取物50-500重量份和番茄红素10-500重量份。
2.根据权利要求1所述的降血脂、降胆固醇的组合物,其特征在于,包括如下重量份的组分:植物甾醇或其类似物400-800重量份、红曲提取物150-300重量份和番茄红素50-200重量份。
3.根据权利要求1所述的降血脂、降胆固醇的组合物,其特征在于,包括如下重量份的组分:植物甾醇或其类似物754重量份、红曲提取物114.9重量份和番茄红素99.5重量份;或
植物甾醇或其类似物682重量份、红曲提取物280重量份和番茄红素99重量份。
4.一种如权利要求1-3任一项所述的降血脂、降胆固醇的组合物的制备方法,其特征在于,按照配方称取原料,混合。
5.一种制剂,其特征在于,以权利要求1-3任一项所述的降血脂、降胆固醇的组合物为活性成分。
6.根据权利要求5所述的制剂,其特征在于,还包括制剂允许的赋形剂或载体;
可选的,所述制剂的形式包括液体制剂和固体制剂;
可选的,所述制剂的形式包括注射剂、片剂、胶囊剂、粉剂、颗粒剂或膏剂。
7.权利要求1-3任一项所述的降血脂、降胆固醇的组合物或权利要求5或6所述的制剂具有如下的用途:
(1)制备降血脂和/或降胆固醇的产品中的用途;
(2)制备预防、缓解、辅助治疗或治疗高血脂和/或高胆固醇的产品中的用途;
(3)制备降低甘油三脂的产品中的用途;
(4)制备降低hmgcra基因表达水平的产品中的用途;
(5)制备减肥的产品中的用途。
8.根据权利要求7所述的用途,其特征在于,所述产品包括食品、食品添加剂或药品。
9.根据权利要求8所述的用途,其特征在于,所述食品包括功能性食品、保健品或普通食品。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211096185.1A CN116327814A (zh) | 2022-09-08 | 2022-09-08 | 一种降血脂、降胆固醇的组合物及其制备方法和用途 |
PCT/CN2022/119213 WO2024050864A1 (zh) | 2022-09-08 | 2022-09-16 | 一种降血脂、降胆固醇的组合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211096185.1A CN116327814A (zh) | 2022-09-08 | 2022-09-08 | 一种降血脂、降胆固醇的组合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116327814A true CN116327814A (zh) | 2023-06-27 |
Family
ID=86882767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211096185.1A Pending CN116327814A (zh) | 2022-09-08 | 2022-09-08 | 一种降血脂、降胆固醇的组合物及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116327814A (zh) |
WO (1) | WO2024050864A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103619329A (zh) * | 2011-04-07 | 2014-03-05 | 利库德有限公司 | 协同组合物及方法 |
CN105878801A (zh) * | 2016-05-10 | 2016-08-24 | 胡铭 | 一种具有降血脂作用的红曲虾青素组合物 |
CN107095974A (zh) * | 2017-06-01 | 2017-08-29 | 中山大学 | 一种降血糖组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1403064B1 (it) * | 2010-11-18 | 2013-10-04 | Mangiapane | Composizione di sostanze per il trattamento di pazienti con ipercolesterolemia e patologie collegate |
CN108771661A (zh) * | 2018-05-29 | 2018-11-09 | 上海天龙生物科技有限公司 | 一种植物甾醇番茄红素软胶囊 |
EP3590356A1 (en) * | 2018-07-05 | 2020-01-08 | Uriach Consumer Healthcare, S.L. | Composition for controlling and reducing blood cholesterol levels |
-
2022
- 2022-09-08 CN CN202211096185.1A patent/CN116327814A/zh active Pending
- 2022-09-16 WO PCT/CN2022/119213 patent/WO2024050864A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103619329A (zh) * | 2011-04-07 | 2014-03-05 | 利库德有限公司 | 协同组合物及方法 |
CN105878801A (zh) * | 2016-05-10 | 2016-08-24 | 胡铭 | 一种具有降血脂作用的红曲虾青素组合物 |
CN107095974A (zh) * | 2017-06-01 | 2017-08-29 | 中山大学 | 一种降血糖组合物 |
Non-Patent Citations (1)
Title |
---|
张伟健等: "PRLC 对气虚血瘀证大鼠血液流变、脂质代谢及肝肾功能的影响", 药学研究, vol. 37, no. 4, pages 194 - 197 * |
Also Published As
Publication number | Publication date |
---|---|
WO2024050864A1 (zh) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Robison et al. | Sexual dimorphism in hepatic gene expression and the response to dietary carbohydrate manipulation in the zebrafish (Danio rerio) | |
Lin et al. | Effects of Momordica saponin extract on alleviating fat accumulation in Caenorhabditis elegans | |
De et al. | Identification of four CCCH zinc finger proteins in Xenopus, including a novel vertebrate protein with four zinc fingers and severely restricted expression | |
Zhang et al. | Isoniazid promotes the anti-inflammatory response in zebrafish associated with regulation of the PPARγ/NF-κB/AP-1 pathway | |
CN109890384A (zh) | 生物素镁组合物和使用方法 | |
Lin et al. | Safety assessment of astaxanthin derived from engineered Escherichia coli K-12 using a 13-week repeated dose oral toxicity study and a prenatal developmental toxicity study in rats | |
Chen et al. | Eucommia ulmoides male flower as a remarkable edible floral resource exerts lifespan/healthspan-promoting effects on Caenorhabditis elegans | |
CN116327814A (zh) | 一种降血脂、降胆固醇的组合物及其制备方法和用途 | |
CN1770975A (zh) | 提高细胞生存能力的方法 | |
CN115671169B (zh) | 一种具有改善睡眠作用的组合物 | |
JP2014509656A (ja) | 炎症および免疫の治療 | |
JP5742050B2 (ja) | Nk細胞活性化剤、及びnk細胞活性化方法 | |
Yagi et al. | Effect of tryptophan metabolites on fluorescent granules in the Malpighian tubules of eye color mutants of Drosophila melanogaster | |
CA2319677A1 (fr) | Medicament pour le traitement des dereglements de l'apoptose contenant des oligosaccharides | |
JP2008303166A (ja) | ゼアキサンチンまたはアスタキサンチンを有効成分とする骨代謝改善剤 | |
WO2013035943A1 (ko) | 항노화 활성을 갖는 베툴린산과 그 유도체 및 이를 함유하는 조성물 | |
WO2019158870A1 (fr) | Combinaison de rhodiole et d'astragale pour le traitement de maladies neurodegeneratives | |
CN115192605B (zh) | 二巯基丁二酸修饰的四氧化三钴纳米颗粒的应用 | |
CN115707478B (zh) | 具有抗衰老功效的组合物及其制备方法和应用 | |
CN114540450B (zh) | 一种调节hprt1基因和oat1蛋白的汉麻仁生物活性肽及其制备方法 | |
RU2813550C1 (ru) | Способ получения смеси биологически активных веществ: биогенных аминов гистамина, триптамина, тирамина, кинуренина, а также производного кинуренина - кинуреновой кислоты | |
KR101379460B1 (ko) | 감태(Ecklonia cava )유래 마이톨과 fucoidan의 혼합물을 유효성분으로 함유하는 아토피 피부염 개선용 화장료 조성물 | |
JP7166965B2 (ja) | bFGF発現増強用組成物 | |
Soleimani et al. | Antidiabetic and Antioxidant Properties of Sea Urchin Echinometra mathaei from the Persian Gulf | |
KR20160024718A (ko) | 폴리펩티드를 함유한 생체 다중효과를 가진 약제학적 조성물 및 그 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |